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Background: Anti–N-methyl-D-aspartate receptor immunoglobulin G antibodies directed against the GluN1 subunit are
considered highly specific for anti-N-methyl-D-aspartate receptor encephalitis, a severe clinical syndrome characterized by
seizures, psychiatric symptoms, orofacial dyskinesia and autonomic dysfunction.
Case presentation: Here we report a 33 year old Caucasian male patient with clinically definite multiple sclerosis who
was found to be positive for anti-N-methyl-D-aspartate receptor antibodies. Rituximab therapy was initiated. On the 18
months follow-up visit the patient was found to be clinically stable, without typical signs of anti-N-methyl-D-aspartate
receptor encephalitis.
Conclusion: Our findings add to the growing evidence for a possible association between anti-N-methyl-D-aspartate
receptor encephalitis and demyelinating diseases.
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NeuroinflammationBackground
Patients with immunoglobulin (Ig) G antibodies to
the GluN1 subunit of the N-methyl-D-aspartate receptor
(NMDAR) develop a characteristic clinical syndrome that
was termed anti-NMDA receptor encephalitis [1]. These
patients may present with acute behavioural changes, dys-
kinesia or seizures followed by a decrease in conscious-
ness, psychosis, central hypoventilation and autonomic
dysregulation. Here we report a male patient who had
signs and symptoms highly suggestive of multiple sclerosis
(MS) and met the McDonald criteria [2] and yet was
found to be seropositive for NMDAR IgG antibodies.
Given the high specificity of this antibody, the question
arises whether NMDAR encephalitis may mimic MS or
whether NMDAR IgG is a coincidental finding either
without clinical significance or indicative of a clinically
silent (prodromal) state of the disease. Nowadays diagnostic* Correspondence: Anne.Waschbisch@uk-erlangen.de
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impose once more the question: treat the patient or his lab
results – or both?Case presentation
This 33 year-old Caucasian male patient presented to our
emergency department with mild left-sided hemiparesis
that had developed within days. Six years prior, he had
been treated for subacute-onset diplopia at another
hospital. At that time, MRI demonstrated several de-
myelinating periventricular lesions with one gadolinium
enhancing lesion. Cerebrospinal fluid (CSF) analysis re-
vealed oligoclonal bands. Following a glucocorticoid pulse
therapy complete remission was reached. He was lost to
follow up and no further MRI scans or neurological exam-
inations were performed since he remained asymptomatic
and felt to be in good health.
Cranial MRI on admission demonstrated multiple T2
hyperintense lesions (periventricular, juxtacortical, infra-
tentorial), one of them with gadolinium enhancement
(Figure 1). Upon comparison to the MRI six years before,ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Magnetic resonance imaging. MR FLAIR imaging
demonstrates multiple hyperintense lesions suggestive of multiple
sclerosis (A-C, E). One of the lesions (arrow) was found to be
Gadolinium (Gd) enhancing on T1 scans (D, F).
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evoked potentials showed prolonged latencies in both eyes.
CSF analysis revealed a borderline pleocytosis (5 cells/μl,
95% lymphocytes). The IgG index (1.3) indicated intra-
thecal IgG synthesis. A polyspecific intrathecal immuno-
globulin synthesis against rubella, varicella and herpes
simplex virus but not measles (MRZH reaction) was de-
tected. Oligoclonal bands were found to be positive in
serum and cerebrospinal fluid with additional bands in the
CSF. Blood work and urine testing were unremarkable
without evidence of chronic infection (syphilis, borreliosis,
HIV, HBV and HCV), vitamin B12 deficiency or systemic
autoimmune disease (ANA, ENA, ANCA, RF, dsDNA and
anti-phospholipid antibodies, ACE). The patient was diag-
nosed with relapsing remitting MS according to the re-
vised McDonald criteria [2] and received a glucocorticoidpulse (5 days, methylprednisolone 1 g/day i.v.) followed by
complete recovery. 3 weeks later he returned complaining
of new-onset paroxysmal tingling and cramping in his left
hand and was found to have tonic spasms that responded
well to another course of glucocorticoids and intermittent
low dose carbamazepine therapy. Given the higher inci-
dence of tonic spasms in neuromyelitis optica compared
to MS [3] we decided to test for aquaporin-4 (AQ4)
autoantibodies before initiation of immunomodulatory
therapy. Serum samples were sent to an accredited com-
mercial laboratory with long-standing experience (Stöcker
Laboratories, Euroimmun AG, Lübeck) that employs a
biochip to test for AQ4 autoantibodies in a cell based
assay. This biochip consists of a mosaic of fixed human
embryonal kidney 239 cells each expressing different
recombinant antigens (AQ4, Glu1 NMDAR, AMPAR,
GABA-bR, LGI, CASPR2, Amphiphysin, GAD, Hu, Ri,
Yo, Tr, MAG, Myelin, Ma/Ta, Glycine receptor) in addition
to frozen sections of rat hippocampus and cerebellum. The
patient turned out to be AQ4 autoantibody negative but
surprisingly IgG directed against the NR1 subunit of the
NMDAR (titre 1:100) was detected and confirmed by a
typical staining pattern on rat brain. Control testing with
an independent serum sample yielded the same result.
A third serum sample was sent to a second laboratory
(A. Vincent, Imunology Laboratory, Churchill Hospital,
Oxford, GB) and confirmed the results and titres.
Further diagnostic tests were performed: Electroenceph-
alography showed a normal alpha-rhythm without evidence
for epileptic activity or slowing. Neuropsychological evalu-
ation (Wechsler Memory Scale Revised Edition; Digit span
forward/backward; Spatial span backward/forward; Logical
memory I, Go/Nogo, Divided attention version I/auditive-
visual) demonstrated normal cognitive functions. A psychi-
atric exploration as well as thorax/adomen CT and spinal
cord MRI were unremarkable. A B cell depleting therapy
with rituximab was started and well tolerated. A complete
B cell depletion was confirmed by immune cell phenotyp-
ing. Since then (18 months) the patient has been monitored
at short intervals and repeatedly been assessed for seizures,
cognitive decline or behavioral changes as well as symp-
toms of MS relapse but was considered clinically stable. In
addition MRI demonstrated paraclinical stability 12 months
after the onset of symptoms. NMDAR Ab testing demon-
strated persistence at an unchanged titre of 1:100.
Discussion
Here we describe a patient with clinically definite MS and
the presence of NMADR serum antibodies. He was
carefully evaluated for seizures, dyskinesia, psychiatric or
neuropsychological symptoms which were all negative.
Thus, the clinical line-up found was best compatible with
relapsing remitting MS and not considered indicative of
NMDAR encephalitis.
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the NMDA receptor, NMDAR IgG serum antibodies are
in general considered highly specific for NMDAR enceph-
alitis. However, depending on the diagnostic test, false
positive IgG serum results have been reported in up to 3%
of healthy controls [4,5]. In our patient, a positive cell
based assay [6], was confirmed by a typical staining
pattern on rat brain tissue, and in another laboratory.
According to previously published studies CSF adds to
the sensitivity [7] and the specificity [4] of NMDAR
antibody tests. Unfortunately CSF was not available to
confirm intrathecal synthesis and the patient declined
to undergo a second lumbar puncture which limits the
significance of our findings. Also unfortunately, we were
unable to obtain high quality images of the IHC/IF stain-
ings done by Labor Stöcker which would have enhanced
our report.
Monosymptomatic disease courses of NMDAR enceph-
alitis (“forms frustes”) have been reported. Accordingly,
NMDAR IgG Ab were recently described at low frequency
(1.7%) in a cohort of epilepsy patients who did not display
other features of encephalitis [8]. Similarily, patients with
isolated psychiatric symptoms at onset or during relapse
were reported [9]. In addition persistence of NMDAR IgG
after an initial episode of encephalitis as well as relapses
following long clinically silent periods have been reported
[10]. Therefore, NMDAR serum IgG may as well precede
the clinical onset of NMDAR encephalitis.
A correlation of serum titers with disease activity is a
subject of ongoing debate, but a recent study show that
higher antibody titers are associated with poor outcome
or the presence of teratoma [7]. Our patient had a rather
low serum titer of 1:100 (normal <1:10) and tumor screen-
ing remained negative.
Anecdotal evidence points towards a possible association
of NMDAR encephalitis with demyelinating disease:
NMDAR IgG have been reported in children with demye-
linating syndromes (ADEM, ON) [11] and extensive
myelitis [12]. In addition two cases of patients that ini-
tially presented with typical symptoms of NMDAR en-
cephalitis and developed a disease closely mimicking
neuromyelitis optica have been reported [13,14] and a
range of demyelinating conditions were reported in case
series in adults and children [15,16].
In contrast a study testing NMDAR IgG antibodies in
a small cohort of MS patients as a disease control failed
to detect the autoantibody [6]. Herpes encephalitis has
been reported as a possible trigger of NMDA receptor anti-
body formation and consecutive encephalitis [17-19]. The
mechanisms remain unknown. However, both molecular
mimicry and breakdown of immunologic tolerance
towards the NMDAR released by neuronal damage in
an inflamed environment have been discussed [17,18].
Whether tissue damage and inflammation in MS mayalso trigger the formation of this antibody remains
speculative.
Conclusion
The growing availability of chip technologies that perform
simultaneous testing of multiple antibodies independent
of the clinical syndrome and with limited confirmatory
tests poses the risk of false-positive results and challenges
clinicians and laboratory physicians alike who have to
decide whether these autoantibodies may indicate an evolv-
ing autoimmune process or represent a clinical non-
significant epiphenomenon. Further research is warranted
to clarify a possible link between demyelinating diseases
and NMDAR encephalitis.
In general, diagnosis of any autoimmune disease neces-
sitates the combination of a compatible clinical picture to-
gether with conformed laboratory findings and treatment
should not be based on laboratory findings alone.
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